CONMED Corporation Announces First Quarter 2022 Financial Results

Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported financial results for Q1 2022, with sales reaching $242.3 million, marking a 4.1% increase year over year. Domestic revenue rose 5.9%, while international revenue grew 2.2%. Diluted EPS was $0.47, up 51.6% from Q1 2021. The company raised its 2022 revenue guidance to between $1.105 billion and $1.150 billion, incorporating $20 million from the recent acquisition of In2Bones Global, subject to regulatory approval. Adjusted diluted EPS guidance is now $3.50 to $3.65.

Positive

• Sales increased by 4.1% year over year to $242.3 million.
• Diluted net earnings per share (EPS) rose by 51.6% to $0.47.
• Raised full-year revenue guidance to $1.105 billion - $1.150 billion.
• Adjusted diluted EPS guidance increased to $3.50 - $3.65.

Negative

• Expected diluted EPS guidance decreased from prior range of $3.60 - $3.85 due to inflation and acquisition dilution.

LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2022.

First Quarter 2022 Highlights

• Sales of $242.3 million increased 4.1% year over year as reported and 4.3% in constant currency.
• Domestic revenue increased 5.9% year over year.
• International revenue increased 2.2% year over year as reported and 2.6% in constant currency.
• Diluted net earnings per share (GAAP) were $0.47, an increase of 51.6% over the first quarter of 2021.
• Adjusted diluted net earnings per share⁽¹⁾ were $0.70, an increase of 11.1% over the first quarter of 2021.

“I am pleased with our start to the year as we generated momentum and finished the quarter on a strong note,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “While we are facing larger than anticipated inflationary pressures, we remain confident in our longer-term prospects for both top and bottom-line growth.”

2022 Outlook

Based on the first quarter results, the Company is raising its revenue guidance for the full year 2022 and now expects revenue between $1.105 billion and $1.150 billion, compared to its prior guidance of between $1.075 billion and $1.125 billion. Based on recent exchange rates, the Company continues to expect foreign exchange to be immaterial to full-year 2022 revenue growth. This new guidance range includes approximately $20 million in revenue in the back half of 2022 related to the acquisition of In2Bones Global, Inc., announced today. The acquisition is subject to customary closing conditions, including receipt of U.S. regulatory approval.

The Company now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.50 to $3.65, compared to its prior range of $3.60 to $3.85. The new guidance range includes the impact of increased inflation and dilution of $0.05 to $0.10 related to the acquisition.

Supplemental Financial Disclosures

⁽¹⁾ A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

Conference Call

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its first quarter 2022 results.

To participate in the conference call, dial 1-844-826-3033 (domestic) or 1-412-317-5185 (international) and enter the conference ID 10166354.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 7:30 p.m. ET on Wednesday, May 4, 2022, until 11:59 p.m. ET on Wednesday, May 18, 2022. To hear this recording, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and enter the replay pin number 10166354.

Consolidated Condensed Statements of Income
(in thousands except per share amounts, unaudited)
		Three Months Ended
		March 31,
		2022				2021
Net sales		$	242,327			$	232,677
Cost of sales			106,336				104,228
Gross profit			135,991				128,449
% of sales			56.1	%			55.2	%
Selling & administrative expense			102,875				98,340
Research & development expense			10,672				10,027
Income from operations			22,444				20,082
% of sales			9.3	%			8.6	%
Interest expense			4,998				10,351
Income before income taxes			17,446				9,731
Provision for (benefit from) income taxes			2,471				(129	)
Net income		$	14,975			$	9,860
Basic EPS		$	0.51			$	0.34
Diluted EPS			0.47				0.31
Basic shares			29,428				28,972
Diluted shares			35,155				31,378

Sales Summary
(in millions, unaudited)
		Three Months Ended March 31,
								% Change
																	Domestic			International
		2022			2021			As Reported			Impact of Foreign Currency			Constant Currency			As Reported			As Reported			Impact of Foreign Currency			Constant Currency
Orthopedic Surgery		$	107.5		$	107.2		0.3	%		0.1	%		0.4	%		2.2	%		-0.7	%		0.2	%		-0.5	%
General Surgery			134.8			125.5		7.4	%		0.3	%		7.7	%		7.5	%		7.3	%		0.9	%		8.2	%
		$	242.3		$	232.7		4.1	%		0.2	%		4.3	%		5.9	%		2.2	%		0.4	%		2.6	%
Single-use Products		$	201.5		$	187.4		7.5	%		0.2	%		7.7	%		6.2	%		9.2	%		0.4	%		9.6	%
Capital Products			40.8			45.3		-9.7	%		0.1	%		-9.6	%		4.1	%		-19.3	%		0.3	%		-19.0	%
		$	242.3		$	232.7		4.1	%		0.2	%		4.3	%		5.9	%		2.2	%		0.4	%		2.6	%
Domestic		$	131.2		$	123.9		5.9	%		0.0	%		5.9	%
International			111.1			108.8		2.2	%		0.4	%		2.6	%
		$	242.3		$	232.7		4.1	%		0.2	%		4.3	%

Reconciliation of Reported Net Income to Adjusted Net Income
(in thousands, except per share amounts, unaudited)
		Three Months Ended March 31, 2022
		Gross Profit				Selling & Administrative Expense				Operating Income				Interest Expense				Tax Expense				Effective Tax Rate			Net Income			Basic EPS			GAAP Adjustments(2)			Diluted EPS
As reported		$	135,991			$	102,875			$	22,444			$	4,998			$	2,471			14.2	%		$	14,975					$	1,715		$	16,690
% of sales			56.1	%			42.5	%			9.3	%
EPS																												$	0.51					$	0.47
Amortization(1)		$	1,500				(6,562	)			8,062				(880	)			2,160							6,782
As adjusted						$	96,313			$	30,506			$	4,118			$	4,631			17.5	%		$	21,757					$	1,715		$	23,472
% of sales							39.7	%			12.6	%
Adjusted Diluted EPS																																		$	0.70
Weighted average common and potential common shares, as reported																													29,428			5,727			35,155
Convertible note hedges(3)																																			(1,412	)
Diluted shares, as adjusted																																			33,743
		Three Months Ended March 31, 2021
		Gross Profit				Selling & Administrative Expense				Operating Income				Interest Expense				Tax Expense/ (Benefit)				Effective Tax Rate			Net Income			Basic EPS			GAAP Adjustments(2)			Diluted EPS
As reported		$	128,449			$	98,340			$	20,082			$	10,351			$	(129	)		-1.3	%		$	9,860					$	-		$	9,860
% of sales			55.2	%			42.3	%			8.6	%
EPS																												$	0.34					$	0.31
Restructuring and related costs (4)			-				(414	)			414				-				109							305
		$	128,449			$	97,926			$	20,496			$	10,351			$	(20	)					$	10,165
Adjusted gross profit %			55.2	%
Amortization(1)		$	1,500				(6,838	)			8,338				(3,561	)			2,969							8,930
As adjusted						$	91,088			$	28,834			$	6,790			$	2,949			13.4	%		$	19,095					$	-		$	19,095
% of sales							39.1	%			12.4	%
Adjusted Diluted EPS																																		$	0.63
Weighted average common and potential common shares, as reported																													28,972			2,406			31,378
Convertible note hedges(3)																																			(1,014	)
Diluted shares, as adjusted																																			30,364
(1) Includes amortization of intangible assets, deferred financing fees and debt discount.
(2) The Company adopted ASU 2020-06, effective January 1, 2022. As a result of the adoption, the Company is required to compute diluted EPS using the if-converted method. Under the if-converted method, the numerator is adjusted for interest expense applicable to the convertible notes (net of tax) and the denominator includes additional common shares assuming conversion.
(3) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company's convertible note hedge transactions.
(4) In 2021, the Company incurred restructuring costs related to restructuring of our sales force.

Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA
(in thousands, unaudited)
		Three Months Ended
		March 31,
		2022				2021
Net income		$	14,975			$	9,860
Provision for (benefit from) income taxes			2,471				(129	)
Interest expense			4,998				10,351
Depreciation			4,032				4,757
Amortization			12,799				13,519
EBITDA		$	39,275			$	38,358
Stock based compensation			4,463				3,387
Restructuring and related costs			-				414
Adjusted EBITDA		$	43,738			$	42,159
EBITDA Margin
EBITDA			16.2	%			16.5	%
Adjusted EBITDA			18.0	%			18.1	%

About CONMED Corporation

CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and the associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks posed to the Company’s business, financial condition, and results of operations by the COVID-19 global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability; the ability of the Company to advance In2Bones Global, Inc.’s product lines following the acquisition; uncertainties as to the timing for completion of the acquisition; the possibility that various conditions to complete the acquisition may not be satisfied or waived; transaction costs in connection with the acquisition; the potential effects of the acquisition on relationships with employees, customers, other business partners or governmental entities; any assumptions underlying any of the foregoing as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2021. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted income tax expense (benefit); adjusted effective income tax rate; adjusted net income, adjusted diluted shares and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, income tax expense (benefit), effective income tax rate, net income, diluted shares and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504006059/en/

CONMED Corporation

Todd W. Garner

Chief Financial Officer

727-214-2975

ToddGarner@conmed.com

Source: CONMED Corporation

FAQ

What were CONMED's Q1 2022 earnings results?

CONMED reported Q1 2022 sales of $242.3 million, with diluted EPS of $0.47, up 51.6% from Q1 2021.

How did CONMED's domestic and international revenue perform in Q1 2022?

Domestic revenue increased by 5.9%, while international revenue grew by 2.2% year over year.

What is CONMED's revenue guidance for full-year 2022?

The company raised its revenue guidance for 2022 to between $1.105 billion and $1.150 billion.

What is the adjusted EPS guidance for CONMED in 2022?

Adjusted diluted EPS guidance is now in the range of $3.50 to $3.65.

What acquisition did CONMED announce in Q1 2022?

CONMED announced the acquisition of In2Bones Global, which is expected to contribute approximately $20 million in revenue.